Skip to main
FIXX
FIXX logo

Homology Medicines (FIXX) Stock Forecast & Price Target

Homology Medicines (FIXX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 17%
Hold 42%
Sell 0%
Strong Sell 0%
Homology Medicines (FIXX) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 17% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Homology Medicines and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Homology Medicines (FIXX) Forecast

Analysts have given Homology Medicines (FIXX) a Buy based on their latest research and market trends.

According to 12 analysts, Homology Medicines (FIXX) has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Homology Medicines (FIXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.